ARCHERY: a prospective observational study of artificial intelligence-based radiotherapy treatment planning for cervical, head and neck and prostate cancer - study protocol.

Journal: BMJ open
PMID: 38149419

Abstract

INTRODUCTION: Fifty per cent of patients with cancer require radiotherapy during their disease course, however, only 10%-40% of patients in low-income and middle-income countries (LMICs) have access to it. A shortfall in specialised workforce has been identified as the most significant barrier to expanding radiotherapy capacity. Artificial intelligence (AI)-based software has been developed to automate both the delineation of anatomical target structures and the definition of the position, size and shape of the radiation beams. Proposed advantages include improved treatment accuracy, as well as a reduction in the time (from weeks to minutes) and human resources needed to deliver radiotherapy.

Authors

  • Ajay Aggarwal
    Institute of Cancer Policy, King's College London Faculty of Life Sciences & Medicine, London, UK.
  • Laurence Edward Court
    MD Anderson Cancer Center, University of Texas, Houston, Texas, USA.
  • Peter Hoskin
    Department of Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Isabella Jacques
    Institute of Clinical Trials and Methodology - MRC CTU at UCL, University College London, London, UK.
  • Mariana Kroiss
    National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, UK.
  • Sarbani Laskar
    Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
  • Yolande Lievens
    Ghent University Hospital, Gent, Belgium.
  • Indranil Mallick
    Tata Medical Center, Kolkata, India.
  • Rozita Abdul Malik
    University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia.
  • Elizabeth Miles
    National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, Northwood, UK.
  • Issa Mohamad
    King Hussein Cancer Center, Amman, Jordan.
  • Claire Murphy
    Institute of Clinical Trials and Methodology - MRC CTU at UCL, University College London, London, UK.
  • Matthew Nankivell
    Institute of Clinical Trials and Methodology - MRC CTU at UCL, University College London, London, UK.
  • Jeannette Parkes
    Division of Radiation Oncology and Medical Physics, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
  • Mahesh Parmar
    Institute of Clinical Trials and Methodology - MRC CTU at UCL, University College London, London, UK.
  • Carol Roach
    Institute of Clinical Trials and Methodology - MRC CTU at UCL, University College London, London, UK.
  • Hannah Simonds
    Division of Radiation Oncology, Stellenbosch University, Tygerberg Academic Hospital, Cape Town, South Africa.
  • Julie Torode
    King's College London, London, UK.
  • Barbara Vanderstraeten
    Ghent University Hospital, Gent, Belgium.
  • Ruth Langley
    Institute of Clinical Trials and Methodology - MRC CTU at UCL, University College London, London, UK.

Keywords

External Resources

Popular Topics
Recent Journals